Meftal Tablets

MEFTAL-SPAS® Injection

MEFTAL-SPAS® Injection is a rapid-acting antispasmodic formulation indicated for the symptomatic relief of gastrointestinal muscle spasms and functional bowel disorders, including irritable bowel syndrome (IBS), particularly where oral administration is not feasible.

Clinical Applications

Irritable Bowel Syndrome

Irritable Bowel Syndrome

Learn More
Acute Gut Spasms

Acute Gut Spasms

Learn More
Severe Abdominal Cramping

Severe Abdominal Cramping

Learn More
Non-Oral Emergency Relief

Non-Oral Emergency Relief

Learn More

More clinical applications:

Gastroenterology Functional bowel disorders and irritable bowel syndrome (IBS) presenting with cramps, bloating, and altered bowel habit.
Emergency & Acute Care Severe gastrointestinal spasms requiring rapid, parenteral relief when oral intake is compromised by nausea or vomiting.
General Medicine Sudden, painful muscle contractions of the stomach and intestine causing acute abdominal discomfort.
In-Patient Care Post-operative or hospitalised spasmodic pain where oral antispasmodics are impractical.

Prescribing Guidelines by Age

MEFTAL-SPAS® product range is formulated to provide age-appropriate dosing across the patient lifecycle. The Injection is reserved for adult acute emergency care under direct medical supervision.

Patient Age Group Recommended Format Typical Clinical Use
Adults (Emergency Care) Injection Severe, sudden spasms and IBS flares requiring rapid onset.

Pharmacological Highlights for the Physician

  • Anticholinergic Mechanism:
    Dicyclomine Hydrochloride blocks acetylcholine at muscarinic receptors, relaxing gastrointestinal smooth muscle and inhibiting spasm.
  • Rapid Onset:
    Parenteral administration typically provides relief within 15 to 30 minutes, making it suited to acute spasmodic episodes.
  • For IM Use Only:
    Administered strictly by intramuscular injection by a trained healthcare professional; never for intravenous use.

Prescribing Information

Generic Name

Dicyclomine Injection IP

(Brand Name: MEFTAL-SPAS® Injection)

Qualitative and Quantitative Composition

MEFTAL-SPAS® Injection

Each ml contains:

Dicyclomine Hydrochloride IP: 10 mg

Benzyl Alcohol IP (as preservative): 2% v/v

Water for Injection IP: q.s.

Dosage Form and Strength

Dosage Form: Injection.

Dosage Strength: Dicyclomine hydrochloride 10 mg per ml (20 mg/ 2 ml ampoule).

Posology and Method of Administration

Adults: MEFTAL-SPAS® Injection must be administered via intramuscular (I.M.) route only.

Do not administer by I.V. or any other route. The recommended dose of dicyclomine is 10 mg to 20 mg up to four times a day.

Treatment with dicyclomine injection should not be given for more than 2 days. If necessary, treatment can be continued with oral formulation or as prescribed by the physician.

Contraindications

MEFTAL-SPAS® Injection is contraindicated in the following:

  • Hypersensitivity to dicyclomine or to any component of the formulation.
  • Infants less than 6 months of age.
  • Nursing mothers.
  • In patients with:
    • Unstable cardiovascular status in acute hemorrhage.
    • Myasthenia gravis.
    • Glaucoma.
    • Obstructive uropathy.
    • Obstructive disease of the gastrointestinal tract (GIT).
    • Severe ulcerative colitis.
    • Reflux esophagitis.

Possible Side Effects (Safety Information)

For detailed quantitative and qualitative composition, therapeutic indications, posology and method of administration, contraindications, special warnings and precautions for use, drug interactions, undesirable effects, overdose, mechanism of action, and pharmacodynamic properties of MEFTAL-SPAS® Injection, download the note.